Background. Pentraxin 3 (PTX3) plays an important role in resistance to Aspergillus infections. Previous studies have suggested that PTX3 polymorphisms influence the risk of invasive aspergillosis among transplantation recipients. This study investigated the association between PTX3 gene polymorphisms and pulmonary aspergillosis in a chronic obstructive pulmonary disease (COPD) population.
that the production of PTX3 is lower in mice with chronic granulomatous disease, but exogenous administration of PTX3 can rescue antifungal resistance and restrain the continuous inflammatory response to the fungus [8] .
PTX3 gene polymorphisms are also considered important risk factors for pulmonary aspergillosis. In Caucasian hematopoietic stem-cell transplantation and solid-organ transplantation patients, several studies have described a link between PTX3 polymorphisms and susceptibility to aspergillosis [9] [10] [11] . However, the association between the PTX3 gene and aspergillosis in COPD patients has not been investigated. In this study, we aimed to analyze the clinical relevance of PTX3 polymorphisms and plasma PTX3 to aspergillosis susceptibility in COPD patients.
METHODS

Study Population
A total of 173 consecutive Chinese inpatients with COPD in Nanjing Jinling Hospital between March 2015 and November 2016 were included in this study. Among them, 36 cases were finally diagnosed with pulmonary aspergillosis with COPD, whereas 137 cases were determined to have COPD without pulmonary aspergillosis (n = 114 patients with stable COPD and n = 23 patients with acute exacerbation COPD). Pulmonary function and disease severity were determined according to the Global Initiative for Chronic Obstructive Lung Disease Guidelines (GOLD, updated 2015) [12] . Subjects with forced expiratory volume in 1 second ≥80%, between 50% and 79%, between 30% and 49%, and <30% of predicted values were designated as GOLD 1, 2, 3, and 4, respectively.
Among the aspergillosis cases, 25 patients were diagnosed with proven (n = 2 patients) or probable (n = 23 patients) acute IPA and 11 patients were diagnosed with CPA (all diagnosed as "probable") according to the updated Infectious Diseases Society of America guideline criteria [13] . All patients have clinical symptoms such as cough, sputum, fever, and chest pain. Furthermore, the presence of radiological features consistent with pulmonary aspergillosis on a computed tomography (CT) scan, such as dense, well-circumscribed lesions with or without a halo sign, an air crescent sign, or cavity. Two proven IPA patients were diagnosed by histopathology (Aspergillus hyphae were found in lung biopsy specimens). Among probable patients, 14 had 2 consecutive positive Aspergillus cultures from qualified sputum specimens, and the other patients had 2 consecutive positive serum or bronchoalveolar lavage fluid galactomannan detection results (at a cutoff value of ≥0.5). All IPA or CPA patients had a clinical response to the treatment using voriconazole. Thus, the diagnosis of pulmonary aspergillosis was convincing. One hundred thirty-seven COPD patients without IPA or CPA were enrolled as controls. Patients who previously underwent hematopoietic stem-cell or solid-organ transplant or who were diagnosed with neutropenia were excluded from the study (Table 1) .
Genotyping Strategy and DNA Extraction
Three single nucleotide polymorphisms (SNPs; rs2305619, rs3816527, and rs1840680) were selected based on previous reports and information from GenBank and HapMap databases. The selected SNPs were located within the coding region of the PTX3 gene and thus may possibly influence protein synthesis.
Peripheral blood from each subject was collected into an ethylene diamine tetraacetic acid tube. Genomic DNA was extracted from peripheral whole blood using a genomic DNA extraction kit (D3471, Omega Bio-Tek, GA, USA) according to the manufacturer's recommendations. All genomic DNAs were stored in a −80°C freezer until analysis. Primers were designed using Primer Premier 5.0 (Premier Biosoft International, Palo Alto, CA). Polymerase chain reaction amplification was performed in an Eppendorf PRO PCR System (Hamburg, Germany). All SNPs were genotyped by the ABI 3730 XL system (Applied Biosystems, NY, USA) . DNA sequences were read by using Chromas 2.23 software (Technelysium Pty Ltd, Tewantin, Australia).
Measurement of Plasma PTX3 Levels
Plasma PTX3 levels were measured using an enzyme-linked immunosorbent assay kit, which was performed according to the manufacturer's protocol (DPTX30, Quantikine Human Pentraxin 3 Immunoassay, R&D, Abingdon, UK).
Statistical Analysis
The genotypic data of each SNP of the control subjects was assessed in terms of Hardy-Weinberg equilibrium by using the χ 2 test. Allelic and genotypic differences among SNPs were evaluated using Pearson's χ 2 or Fisher's exact test. The strength of 
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RESULTS
Association Between PTX3 Genetic Variants and Risk of Aspergillosis
No significant difference was observed in terms of sex and mean ages between the case and control groups. Pulmonary function and other baseline features also did not differ from each other ( Table 1) . Three SNPs (rs2305619, rs3816527, and rs1840680) of the controls were consistent with Hardy-Weinberg equilibrium. The minor allele frequencies of all of the SNPs in this group were >5% (Table 2) .
We first analyzed the genotypic distribution of SNPs among all aspergillosis and COPD patients. Genotypic differences in rs1840680 between the case and control groups were statistically significant (P < .001). At the same time, calculation for odds ratios in accordance with a recessive model for rs1840680 suggests that the COPD patients who were homozygous for AA homozygote had a higher risk for pulmonary aspergillosis. For the other 2 SNPs (rs2305619 and rs3816527), no differences in genotypic frequencies were observed (Table 3) . Linkage disequilibrium estimation analyses were performed with Haploview 4.2. Linkage disequilibrium strength between PTX3 rs2305619 and rs3816527 was exceedingly high, with D' = 0.96 ( Figure  1A) . Comparison of the frequencies of the 3 haplotypes of PTX3 block1 between the aspergillosis and non-aspergillosis COPD groups indicated that these haplotypes were not associated with pulmonary aspergillosis (Table 4) .
We then performed subgroup analysis and calculated for the IPA and the CPA as the cases, respectively, using 137 COPD patients as controls. The recessive model for SNP rs1840680 suggests that AA homozygosity might increase the risk for IPA (P = .0004; OR, 5.94; 95% CI, 2.31-15.31) or CPA (P = .04; OR, 4.32; 95% CI, 1.14-16.41) ( Table 5 ) in COPD patients. No significant differences in genotypic frequencies of the other 2 SNPs were observed. The distribution of haplotypes (rs2305619 and rs3816527) also showed no significant differences (P > .05) ( Table 4 ).
PTX3 May be Potentially Used as a Biomarker for IPA in COPD Patients
We compared the plasma PTX3 levels of patients in different groups. In the control group, the patients were divided into stable COPD and acute COPD exacerbation. Plasma PTX3 levels decreased in COPD patients with worse lung function (GOLD1 vs GOLD2 vs GOLD3 vs GOLD4: 2.03 ± 2.34 vs 1.73 ± 1.90 vs 1.50 ± 1.65 vs 1.01 ± 0.73; P = .67) (Figure 2A ). However, no statistical differences were observed. No significant differences in plasma PTX3 values were observed between patients with stable COPD and acute exacerbation COPD (1.51 ± 1.68 ng/mL vs 2.13 ± 1.68 ng/mL; P = .11). Interestingly, plasma PTX3 levels significantly increased in patients with COPD with aspergillosis compared with patients with COPD alone. In the aspergillosis group, the plasma PTX3 levels of patients with IPA were significantly higher than in patients with stable COPD, acute exacerbation COPD, and CPA patients (7.89 ± 4.08 ng/mL vs 1.51 ± 1.68 ng/mL, P < .001; 7.89 ± 4.08 ng/mL vs 2.13 ± 1.68 ng/mL, P < .001; 7.89 ± 4.08 ng/mL vs 4.18 ± 4.02; P = .02) ( Figure 2C ). However, compared with the stable COPD and acute exacerbation COPD groups, no statistical difference in plasma PTX3 level in CPA patients was observed. Figure 3 shows that the plasma PTX3 levels of patients with the rs1840680 AA genotype or AG+GG genotype did not differ from each other in the control group (1.77 ± 2.25 ng/mL vs 1.59 ± 1.61 ng/mL; P = .69). However, all aspergillosis patients with the AA genotype (vs AG and GG genotypes) showed lower PTX3 levels (5.00 ± 2.76 ng/mL vs 8.01 ± 4.90 ng/mL; P = .04). Similar results were obtained in the IPA group (5.37 ± 2.60 ng/ mL vs 9.87 ± 4.00 ng/mL; P = .004). However, the PTX3 plasma levels showed no statistical difference between patients with the rs1840680 AA genotype and AG+GG genotype in the CPA group (3.97 ± 3.35 ng/mL vs 4.30 ± 4.62 ng/mL; P = .90).
Association of rs1840680 Polymorphisms With Plasma PTX3 Levels
DISCUSSION
This study aimed to investigate the association between PTX3 gene polymorphisms and pulmonary aspergillosis in the Chinese population by analyzing 3 SNPs (rs2305619, rs3816527, and rs1840680) in pulmonary aspergillosis and control subjects. Using a recessive model, a significant association between the rs1840680 polymorphism within the PTX3 gene and an increased risk for pulmonary aspergillosis were observed. PTX3 is a soluble pattern recognition receptor that is secreted by various cells [14] . PTX3 can bind to aspergillus fumigatus conidia by identifying galactomannan units, thereby serving as an opsonizing factor for activating the complement system and subsequent phagocytosis [15] . A number of studies have shown that PTX3 plays a key role in innate immunity to aspergillus infections [16] [17] [18] . A previous study described a significant association between the rs2305619 GG homozygote, rs3816527 AA homozygote, and an increased risk for the development of invasive aspergillosis among hematopoietic stem-cell transplant recipients. However, in this study, the frequency of the rs1840680 AA homozygote was significantly higher in COPD patients with pulmonary aspergillosis compared with those with COPD alone. No differences in genotypic frequencies involving rs2305619 and rs3816527 were observed between aspergillosis patients and the controls.
Linkage disequilibrium analyses indicate that the haplotypes that harbor rs2305619 and rs3816527 within the PTX3 gene are not associated with an increased risk of Aspergillus infection (including IPA and CPA) in COPD patients. However, a number of studies have reported associations between haplotype h2/h2 (rs2305619-rs3816527: G-A/G-A) in PTX3 gene and susceptibility to invasive aspergillosis among immunocompromised patients [9] [10] [11] . This study involved a Chinese COPD population whose clinical condition and immune state are different. Previous research mainly focused on IPA patients. In our study, we chose not only IPA but also CPA (chronic cavity pulmonary aspergillosis and chronic fibrosing pulmonary aspergillosis) as subjects. Unlike aspergilloma, these types of CPA have a similar pathogenesis to IPA but a longer duration. Consequently, we obtained similar results between the IPA and CPA subgroups in terms of genotype susceptibility to aspergillosis. In our study, the plasma PTX3 levels in the IPA group were significantly higher than those in the controls. Another finding indicates that the most frequent genotype, AA, is associated with lower plasma PTX3 levels compared with the AG and GG genotypes in the IPA group. In the CPA group, the plasma PTX3 level was higher than in controls, although this was not statistically significant. The plasma PTX3 levels of AA genotype patients were lower than that of AG and GG genotype patients, although no statistical difference was detected. We consider PTX3 to be an acute-phase protein. The PTX3 storage may have been exhausted, and the released PTX3 may have decayed over time in CPA patients, thereby resulting in a smaller difference. There is therefore a need to increase the sample size of CPA patients to verify this result in a future investigation.
No correlation between plasma PTX3 levels and severity of stable COPD was observed in the control group. This observation is in agreement with the findings of a previous report [19] . A previous report indicated that PTX3 levels are elevated in patients with hematological disorders and invasive aspergillosis [18] . In another study, plasma PTX3 levels significantly increased upon fungal infection, whereas C-reactive protein levels did not [20] . These findings suggest that PTX3 plays an additional role in the immune response toward aspergillus. Furthermore, PTX3 may be potentially used in the diagnosis of IPA in COPD patients.
This study certainly has some limitations. First, this study only examined a small number of patients with pulmonary aspergillosis. Second, the subjects were from a single center in Nanjing, China. It is possible that ethnic and genetic differences may also influence the association between PTX3 polymorphism and Figure 3 . Plasma PTX3 levels of patients with different genotypes of rs1840680. The PTX3 plasma levels of pulmonary aspergillosis patients with the AA genotype were lower than those with the AG+AA genotypes. The same results were obtained in the invasive pulmonary aspergillosis group. However, no difference between the AA and AG+AA genotypes in chronic pulmonary aspergillosis patients was observed. *P < .05; **P < .01. Figure 2 . Plasma PTX3 levels of pulmonary aspergillosis patients and chronic obstructive pulmonary disease (COPD) controls. A, Plasma PTX3 levels were lower in COPD patients with worse lung function. However, no statistical differences were observed. B, Plasma PTX3 levels of patients with pulmonary aspergillosis were higher than those in the other 2 groups. C, The plasma PTX3 levels of patients with invasive pulmonary aspergillosis were significantly higher than those with stable COPD, AECOPD, and chronic pulmonary aspergillosis (CPA). However, compared with the stable COPD and AECOPD groups, no statistical difference in plasma PTX3 level in CPA patients was observed. **P < .01; ***P < .001. Abbreviations: AECOPD, acute exacerbation of chronic obstructive pulmonary disease; COPD, chronic obstructive pulmonary disease; CPA, chronic pulmonary aspergillosis; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IPA, invasive pulmonary aspergillosis.
plasma PTX3 levels. Further study is necessary to confirm these results.
The PTX3 rs1840680 polymorphisms are strongly associated with susceptibility to pulmonary aspergillosis in COPD patients, as validated by actual measurements of plasma PTX3 levels. Moreover, plasma PTX3 levels may be useful in the diagnosis of IPA in COPD patients.
Notes
